The latest announcement is out from BeiGene Ltd ( (HK:6160) ).
BeiGene, Ltd. announced it will release its unaudited financial results for the first quarter of 2025 on May 7, 2025, following the trading hours of the Hong Kong Stock Exchange. The announcement will be followed by a conference call hosted by BeiGene management, providing stakeholders with insights into the company’s financial performance and strategic direction.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates in the pharmaceutical industry with a market focus on oncology therapies.
YTD Price Performance: 28.39%
Average Trading Volume: 5,053,159
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$216.8B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.